Published on December 8, 2009 at 7:44 AM
Semafore Pharmaceuticals today reported encouraging data from a Phase I
dose-escalation trial of SF1126 in patients with relapsed and refractory
myeloma. SF1126 is a novel small molecule inhibitor of
phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin
(mTOR), two key members of the PI3K signaling pathway that is vital to
several essential biological processes, such as cell proliferation and
survival. PI3K is commonly altered in human cancers, making inhibition
of the target attractive for cancer therapy. Data were presented during
the 51st American Society of Hematology (ASH) Annual Meeting in New
Orleans, LA.
“The data from this trial demonstrates that SF1126 suppresses the
pathway in tumor cells at well-tolerated doses,” said Principal
Investigator, Sagar Lonial, MD, Associate Professor of Medicine, at the
Winship Cancer Institute of Emory University. “We are encouraged by
these preliminary results which support a dose level to move into
follow-on combination studies.”
"Both the Multiple Myeloma Research Foundation (MMRF), through its
Biotech Investment Award program (LEAD), and the Multiple Myeloma
Research Consortium (MMRC) are proud to have contributed to this trial
as it aligns with our commitment to expand the portfolio of treatment
options for multiple myeloma patients - especially those aimed at
effectively treating patients who have suffered a relapse," said Kathy
Giusti, Founder and Chief Executive Officer of the MMRF and MMRC, and a
myeloma patient.
Source Semafore Pharmaceuticals, Inc.
357c71ce-9a30-4cad-b762-bc60ec668e10|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Biotechnology, Bone, Bone Marrow, Cancer, Cell, Cell Proliferation, Chronic Lymphocytic Leukemia, Hematology, Insulin, Investment, Leukemia, Lymphoma, Multiple Myeloma, Myeloma, Nausea, Oncology, Rapamycin, Vomiting, Xenograft